APTO Stock Performance, Insider Transaction and News

APTO - Aptose Biosciences, Inc.

Market Cap	69.93M	P/E	-	EPS this Y	38.40%	Ern Qtrly Grth	-
Income	-56.15M	Forward P/E	-1.72	EPS next Y	2.20%	50D Avg Chg	17.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-1.00%
Dividend	N/A	Price/Book	1.49	EPS next 5Y	-	52W High Chg	-51.00%
Recommedations	1.70	Quick Ratio	5.41	Shares Outstanding	92.29M	52W Low Chg	76.00%
Insider Own	2.72%	ROA	-45.83%	Shares Float	77.43M	Beta	1.56
Inst Own	31.80%	ROE	-82.88%	Shares Shorted/Prior	782.38K/1.01M	Price	0.76
Gross Margin	-	Profit Margin	-	Avg. Volume	329,937	Target Price	7.80
Oper. Margin	-	Earnings Date	Mar 20	Volume	268,562	Change	1.61%

Healthcare | Biotechnology | Canada

About Aptose Biosciences, Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences, Inc. News

01/30/23	Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
12/30/22	We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully
12/28/22	Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
12/12/22	Aptose Biosciences Establishes New At-The-Market Facility
12/11/22	Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
12/07/22	Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
11/14/22	Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
08:10 AM	Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
11/01/22	Aptose Reports Results for the Third Quarter 2022
10/18/22	Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
09/30/22	Horizon (HZNP) Completes Enrollment in Phase IV TED Study
09/29/22	Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
09/28/22	Merck's (MRK) Keytruda Gets Four New Approvals in Japan
09/27/22	Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223
09/27/22	Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
09/21/22	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
09/20/22	Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication
09/19/22	Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
09/14/22	Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
09/13/22	Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

APTO Chatroom

KOPRO1 Posted - 2 hours ago

$APTO need volume based on tightness of pivot points

AVAVAV Posted - 8 hours ago

$APTO 🆙

AVAVAV Posted - 11 hours ago

$APTO UP!

JohnnnyOnTheSpot Posted - 1 day ago

$APTO didn’t go up with XBI but went down with XBI 😂😂

AVAVAV Posted - 1 day ago

$APTO

JohnnnyOnTheSpot Posted - 1 day ago

$APTO price action very bad for how bullish XBI has been

AVAVAV Posted - 1 day ago

$APTO 🔥🔥🔥🔥

Take0ff Posted - 1 day ago

$APTO break through point the market is with us. Where my bag holders at? 🙌🏻 y’all with me

JohnnnyOnTheSpot Posted - 2 days ago

$APTO 🥶

AVAVAV Posted - 2 days ago

$APTO Go!

JohnnnyOnTheSpot Posted - 01/31/23

$APTO rough, literally can’t go up

AVAVAV Posted - 01/31/23

$APTO

AlertsAndNews Posted - 01/30/23

Gappers in after hours trading, $PBLA $VBIV $APTO $QBTS $SHFS 📈✅

Breezy24K Posted - 01/30/23

30 January BioPharma Pipeline Updates [1] $VERA Phase 2b patient enrollment completed, noted July 6, 2022. Phase 2b interim analysis reported that in the atacicept 150 mg dose group achieved a 47% mean reduction in proteinuria from baseline and a 48% delta versus placebo, noted January 30, 2023. Phase 3 trial planned for 1H 2023. Market Cap $227.1 million $APTO Phase 1/2 additional data reported that 7 patients with a reported best response of composite complete remission and 1 with partial remission (PR), noted December 12, 2022. Phase 1/2 data reported 3 of 8 (37.5%) patients achieved a durable composite complete response, noted December 13, 2021. Phase 1/2 additional data reported eight CRs and favorable safety achieved at three separate dose levels, noted June 3, 2022. Phase 1/2 120mg monotherapy dosing initiated, noted January 30, 2023. Market Cap $68.4 million

AVAVAV Posted - 01/30/23

$APTO

Gilbert_Godbull Posted - 01/30/23

$APTO picked up more at .72, once the trials are finished will be be rocking 5+

STCKPRO Posted - 01/30/23

$APTO NEW ARTICLE : Analysts’ Top Healthcare Picks: Aptose Biosciences (APTO), CureVac (CVAC) https://www.stck.pro/news/APTO/41638478

Gilbert_Godbull Posted - 01/30/23

$APTO down on good news? Who the hell is manipulating this stock?

intrader Posted - 01/30/23

$APTO Patience, looking for $1.15 later.

intrader Posted - 01/30/23

$APTO I'm in at $.72..

stockilluminati Posted - 01/30/23

$APTO https://www.stockilluminati.com/apto/filings.php - Aptose Biosciences, Inc. - Common Shares files form 8-K today, check out the details.

AVAVAV Posted - 01/30/23

$APTO NEWS! 🚀🚀🚀🚀

ChartMill Posted - 01/30/23

$APTO: Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia https://www.chartmill.com/stock/quote/APTO/news?utm_source=stocktwits&utm_medium=pressRelease&utm_content=APTO&utm_campaign=social_tracking

cctranscripts Posted - 01/30/23

Aptose Initiates Dosing Of Tuspetinib In Aptivate Expansion Trial In Patients With Acute Myeloi https://www.conferencecalltranscripts.org/summary/?id=11736947 $APTO

EarningsInsider Posted - 01/30/23

Aptose Biosciences Inc. Files SEC Form 8-K $APTO https://www.marketbeat.com/stocks/NASDAQ/APTO/sec-filings/

Last10K Posted - 01/30/23

$APTO just filed with the SEC a Regulated Disclosure and a Financial Exhibit https://last10k.com/sec-filings/apto/0001171843-23-000530.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=apto

HorsePicks Posted - 01/30/23

$APTO:Aptose Initiates Dosing Of Tuspetinib In APTIVATE Expansion Trial In Patients With Acute Myeloid Leukemia

fla Posted - 01/30/23

$APTO [15s. delayed] filed form 8-K on January 30, 07:05:16 https://s.flashalert.me/dse0ax

Quantisnow Posted - 01/30/23

$APTO 📜 Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits https://quantisnow.com/i/3969811?utm_source=stocktwits 45 seconds delayed.

Newsfilter Posted - 01/30/23

$APTO Form 8-K: Regulation FD Disclosure.On January 30, 2023, the Registrant issued a press release the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “file.. https://newsfilter.io/a/87d5fe2394ce05c1b030054d73d7ba8f

Analyst Ratings

RBC Capital	Outperform	Nov 2, 22
RBC Capital	Outperform	May 10, 22
HC Wainwright & Co.	Buy	Dec 21, 21
HC Wainwright & Co.	Buy	Nov 12, 21
Oppenheimer	Outperform	Mar 24, 21
Maxim Group	Buy	Feb 20, 20
Piper Sandler	Overweight	Jan 9, 20
H.C. Wainwright	Buy	Aug 7, 19
Oppenheimer	Outperform	Jan 25, 19

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Payne Fletcher	SR VP & Chief Fin. O.. SR VP & Chief Fin. Officer	Sep 19	Buy	0.6775	10,000	6,775	10,000	09/21/22
-	- -	Aug 05	Buy	2.65	57,199	151,577	8,948,275	08/05/21
-	- -	Aug 05	Sell	2.62	60,000	157,200	8,888,275	08/05/21
Whitehead Warren	Director Director	Dec 28	Option	2.01	20,000	40,200	60,000	12/28/20
Whitehead Warren	Director Director	Dec 28	Sell	4.06	20,000	81,200	40,000	12/28/20